Triazolam 0.5 mg was administered to 11 dialysis patients and 11 age, weight and sex matched controls. Peak plasma concentrations (Cmax) were higher in control subjects, but there were no other differences between the groups. When dialysis patients took triazolam with 3600 mg aluminium hydroxide suspension, Cma, and AUC were increased into the range observed in control subjects. It appears that triazolam can be used at normal doses in patients with renal dysfunction, without regard to interaction with aluminium hydroxide gel, or to alterations in elimination.
Introduction
Triazolam is a relatively new benzodiazepine which is approved for short term treatment of insomnia. Like other benzodiazepines, triazolam is metabolized in the liver (Eberts etal., 1981) . It is generally proposed that drugs which are metabolized to inactive forms can be administered in normal doses to patients with chronic renal failure. However, the pharmacokinetics of triazolam in renal failure have not been determined.
Most dialysis patients must take aluminium hydroxide preparations to reduce absorption of dietary phosphate. Previously, antacids have been shown to delay or decrease the absorption of chlordiazepoxide (Greenblatt etal., 1976) and diazepam (Greenblatt et al., 1978 Triazolam concentrations were determined by a modification of the electron-capture gas chromatographic method of Greenblatt et al. (1981) . Because plasma samples from the dialysis patients contained unidentified compounds which interfered with the assay, two cleanup steps were added. After mixing and centrifuging 2 ml of sample with 6 ml of 1.5% iso-amyl alcohol in toluene, the organic layer was transferred to a tube containing 1 ml of 0.1 N sulphuric acid. This was mixed for 15 s and centrifuged for 2 min at 2000 rev/min. The aqueous layer was removed and discarded. Sodium carbonate (1 ml, 0.5 M) was added to the organic portion, the mixture was vortexed, centrifuged, and the organic layer transferred to a siliconized 10 ml conical centrifuge tube. Samples were placed in a 55°C water bath and evaporated to dryness under nitrogen. To each tube, 50 ,il of 1.5% iso-amyl alcohol in toluene and 5 ,l of purified soy phosphatides (Asolectin) in benzene were added. The triazolam standard, controls, blanks, and patient samples were all prepared by this same procedure. The prepared samples were assayed with a HewlettPackard 5713 gas chromatograph with a linearized electron capture detector. Because of the range of concentrations over which triazolam was measured, two sets of standard curves (0 to 2.0 ng/ml and 2.0 to 20.0 ng/ml) were constructed each time the assay was performed. The coefficient of variation of the triazolam assay for the low and high curves combined was 8.7%. The lower limit of the assay was 0.2 ng/ml using a 2 ml sample. A triazolobenzodiazepine analogue, U-31485, was used as the internal standard.
Data analysis
Pharmacokinetic parameters were determined by standard methods (Gibaldi & Perrier, 1982 observed in azotemic patients compared to control subjects (Gedde-Dahl & Flatmark, 1975 (Konishi et al., 1982) . Solution pH determines the relative amounts of triazolam and the open ring moiety at equilibrium. At a pH above 5, little hydrolysis occurs and the mixture contains more than 99% closed ring triazolam. The lower the pH, the more rapid the hydrolysis reaction, and the higher the concentration of the open ring benzophenone. Although the reaction is reversible, the half-time of cyclization which results in reformation of the closed ring triazolam is about 80 min (Konishi et al., 1982) . If absorbed in the open ring form, metabolism can occur directly, without cyclization to triazolam. This effectively reduces systemic availability of triazolam.
We postulate that a relatively high basal gastric acid secretion in our dialysis patient population resulted in formation of the open ring structure, decreasing the bioavailability of triazolam when taken alone. The 3600 mg dose of aluminium hydroxide (AlternaGel) administered in this study is approximately equivalent in acid neutralizing capacity to 27 ml Mylantag or 56 ml (Anon., 1982) , and could be expected to raise gastric pH, limiting the extent of triazolam hydrolysis.
Our observations and hypothesis parallel those of Elwood etal. (1983) , who reported that ranitidine increased the bioavailability of midazolam, a benzodiazepine also subject to benzophenone formation. When Abernethy et al. (1983) evaluated the effect of cimetidine on triazolam kinetics, they found that cimetidine did not alter half-life, but tended to increase the peak concentration, while significantly increasing area under the curve. Although they attributed this to decreased first pass effect, their findings are consistent with our hypothesis of increased pH and decreased triazolam hydrolysis.
In conclusion, renal disease does not affect triazolam elimination. When triazolam is administered either with water or with AHG, it is rapidly absorbed, with no difference in tmax.
Aluminium hydroxide gel enhances the absorption of triazolam in dialysis patients. Since concentrations were increased with coadministration of AHG into the range observed in control subjects but not 
